Rafferty Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Rafferty Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-77,078	Closed	-$8.92M	–	1111
2023 Q3	$8.92M	Sell	77,078 -6,707	-8%	-$721K	0.05%	253
2023 Q2	$8.62M	Buy	83,785 +21,919	+35%	+$2.31M	0.05%	240
2023 Q1	$6.75M	Sell	61,866 -21,019	-25%	-$2.32M	0.05%	303
2022 Q4	$9.43M	Sell	82,885 -22,000	-21%	-$1.83M	0.08%	190
2022 Q3	$6.49M	Buy	104,885 +60,154	+134%	+$4.2M	0.07%	252
2022 Q2	$3.57M	Sell	44,731 -8,333	-16%	-$789K	0.03%	353
2022 Q1	$5.58M	Buy	53,064 +650	+1%	+$63.3K	0.03%	361
2021 Q4	$5.65M	Buy	52,414 +23,496	+81%	+$2.56M	0.03%	339
2021 Q3	$3.17M	Buy	28,918 +956	+3%	+$99.2K	0.02%	447
2021 Q2	$2.62M	Buy	27,962 +23,794	+571%	+$2.19M	0.02%	570
2021 Q1	$384K	Sell	4,168 -2,231	-35%	-$188K	﹤0.01%	1025
2020 Q4	$468K	Buy	6,399 +1,029	+19%	+$76.5K	﹤0.01%	699
2020 Q3	$417K	Sell	5,370 -1,117	-17%	-$76.9K	0.01%	737
2020 Q2	$361K	Buy	+6,487	New	+$278K	0.01%	788
2020 Q1	–	Sell	-12,104	Closed	-$438K	–	896
2019 Q4	$438K	Sell	12,104 -7,072	-37%	-$217K	0.01%	710
2019 Q3	$522K	Buy	19,176 +8,393	+78%	+$217K	0.01%	657
2019 Q2	$259K	Buy	+10,783	New	+$274K	﹤0.01%	760

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rafferty Asset Management's HZNP Position: Q4 2023 in Review

Rafferty Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 77,078 shares — an estimated $8.92M sold.

Rafferty Asset Management first reported a position in HZNP in Q2 2019 and held it in 17 quarters. The position peaked at $9.43M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Rafferty Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Rafferty Asset Management sold 77,078 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $8.92M.
Rafferty Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2019 and held it in 17 quarters.
Rafferty Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $9.43M in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Rafferty Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.